An oral H2S nanotherapeutics for hypertensive chronic kidney disease via synergistic antihypertensive and renoprotective activities

Authors: Zhong Shao, Ke Li, Hao Guo, Yangyang Cheng, Shiyong Zhang

https://doi.org/10.1016/j.jconrel.2025.114419

Published in: Journal of Controlled Release (2025)

Tags: Nanodrug, hypertensive chronic kidney disease, renal fibrosis, pharmacokinetics